GSK books £121m in Australian Rx deal with Aspen
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to make a post-tax gain of £121 million following its latest divestment, in which it is selling a basket of 25 older brands for the Australian market to Aspen Global. The products, non-promoted and genericised drugs which GlaxoSmithKline terms "classic brands", generated sales of £83 million in 2011 and £31 million in the first half of 2012. Revenues have been declining on the products due to local price reductions and generic competition.